DCF Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

DCF Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.13M	Buy	7,000 +1,000	+17%	+$466K	0.83%	30
2025 Q4	$2.72M	Buy	+6,000	New	+$2.59M	0.73%	38

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

DCF Advisers's VRTX Position: Q1 2026 in Review

DCF Advisers increased its Vertex Pharmaceuticals (VRTX) stake by 17% in Q1 2026, buying an estimated $466K and bringing the position to 7,000 shares worth $3.13M. The position accounts for 0.83% of the portfolio, ranked #30.

DCF Advisers first reported a position in VRTX in Q4 2025 and has held it in 2 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

DCF Advisers held 7,000 shares of Vertex Pharmaceuticals worth $3.13M as of Q1 2026.
DCF Advisers bought 1,000 Vertex Pharmaceuticals shares in Q1 2026, an estimated $466K.
Vertex Pharmaceuticals made up 0.83% of DCF Advisers's portfolio in Q1 2026, its #30 holding.
DCF Advisers first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on DCF Advisers's 13F filing for Q1 2026, filed 11 May 2026.